Alveolar echinococcosis, caused by Echinococcus multilocularis infection, is a highly deadly zoonotic parasitic disease. As a benzimidazole compound, albendazole has a strong and broad-spectrum anti-parasitic action. For alveolar echinococcosis patients that are unwilling to receive surgical treatment, lose the timing for surgery, or are intolerant to surgery due to poor physical status, administration of albendazole may delay disease progression. Recently, a large number of advances have been achieved in experimental studies on alveolar echinococcosis. In order to increase the understanding of the therapeutic efficacy of albendazole for alveolar echinococcosis, this review summarizes the advances in albendazole treatment for alveolar echinococcosis, so as to provide insights into the clinical treatment of alveolar echinococcosis with albendazole.
[摘要] 多房棘球蝴病是由多房棘球绦虫感染引起的一种高致死率人兽共患寄生虫病。阿苯达唑为苯并咪唑类化合物 之一, 具有强大的杀灭寄生虫作用, 且驱虫谱较广。对于不愿接受手术治疗、失去手术机会或身体状态差而无法耐受手 术的多房棘球蝴病患者, 使用阿苯达唑药物治疗可一定程度上延缓疾病进展。近年来, 多房棘球蝴病相关实验研究取得 大量成果。本文回顾了相关文献并对阿苯达唑治疗多房棘球蝴病研究进展进行综述, 以期增加对阿苯达唑治疗多房棘 球蝴病效果的认识, 为未来用于临床治疗奠定基础。.
Keywords: Albendazole; Alveolar echinococcosis; Combination therapy.